Assembly Biosciences’ (ASMB) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Assembly Biosciences (NASDAQ:ASMB) in a report published on Tuesday morning, MarketBeat Ratings reports. They currently have a $50.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Assembly Biosciences’ Q3 2026 earnings at ($0.44) EPS, Q4 2026 earnings at $3.19 EPS, FY2026 earnings at $2.28 EPS, Q1 2027 earnings at $0.02 EPS, Q2 2027 earnings at ($0.86) EPS, Q3 2027 earnings at ($0.87) EPS, Q4 2027 earnings at $1.63 EPS and FY2027 earnings at ($0.02) EPS.

A number of other research firms have also commented on ASMB. Wall Street Zen lowered Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a report on Friday, July 17th. Mizuho set a $45.00 target price on Assembly Biosciences and gave the stock an “outperform” rating in a research note on Monday, June 15th. Finally, Guggenheim restated a “buy” rating and issued a $43.00 target price on shares of Assembly Biosciences in a research note on Thursday, May 28th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Assembly Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.00.

Assembly Biosciences Trading Down 0.9%

Shares of ASMB stock opened at $33.53 on Tuesday. The firm’s 50 day moving average is $26.88 and its 200 day moving average is $27.55. The stock has a market capitalization of $682.67 million, a P/E ratio of 32.87 and a beta of 1.10. Assembly Biosciences has a 12 month low of $20.23 and a 12 month high of $39.71.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.52. Assembly Biosciences had a negative net margin of 0.06% and a negative return on equity of 0.02%. The business had revenue of $13.37 million during the quarter, compared to analyst estimates of $8.60 million. On average, equities analysts predict that Assembly Biosciences will post 2.28 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Acadian Asset Management LLC increased its holdings in shares of Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after purchasing an additional 6,823 shares during the period. Geode Capital Management LLC raised its position in shares of Assembly Biosciences by 6.9% in the second quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company’s stock worth $925,000 after buying an additional 3,312 shares in the last quarter. Vanguard Group Inc. boosted its stake in Assembly Biosciences by 97.8% during the third quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock valued at $12,854,000 after buying an additional 248,287 shares during the period. ADAR1 Capital Management LLC purchased a new position in Assembly Biosciences during the third quarter worth about $485,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in Assembly Biosciences during the third quarter worth about $3,120,000. 19.92% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Assembly Biosciences

Here are the key news stories impacting Assembly Biosciences this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $50 price target, implying substantial upside from recent trading levels. The firm raised its FY2026 EPS estimate to $2.28 from $1.90 and improved its Q3 2026, Q1 2027, Q2 2027, Q3 2027 and FY2027 forecasts. HC Wainwright analyst estimates
• Positive Sentiment: Analysts collectively rate Assembly Biosciences a Moderate Buy, while HC Wainwright separately reiterated its Buy recommendation. Consensus analyst rating HC Wainwright Buy rating
• Positive Sentiment: Zacks cited positive earnings-estimate revisions and momentum factors, noting that the average Wall Street price target suggests approximately 40.7% potential upside. Zacks cautioned that price targets are not always reliable predictors. Assembly Biosciences analyst price target
• Neutral Sentiment: The latest momentum-focused coverage presents ASMB as a potential pick for momentum investors, reinforcing the stock’s recent strength but offering no new clinical, regulatory or operating catalyst. Assembly Biosciences momentum coverage
• Negative Sentiment: HC Wainwright reduced its Q4 2026 EPS estimate to $3.19 from $3.69 and trimmed its Q4 2027 forecast to $1.63 from $1.66. These cuts suggest some uncertainty around future quarterly profitability, despite the firm’s overall upward revisions and Buy rating.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.